(1888PressRelease)
September 16, 2009 - The data were presented this week at the European Respiratory Society (ERS) 2009 Annual Congress in Vienna, and build on those presented at the American Thoracic Society (ATS) Annual Meeting earlier this year.
"QAB149 has the potential to be recognized as the best bronchodilator for COPD by providing patients with significantly greater lung function improvement and reductions in breathlessness compared to other bronchodilators," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "We also plan for QAB149 to form the foundation of a new portfolio of products, designed to improve patients' respiratory health."
At 12 weeks of treatment, QAB149 150 µg and 300 µg improved trough FEV1[§], a key measure of lung function, by 50 ml and 40 ml respectively over tiotropium 18 µg (p
###
